Pre-Diagnosis FEV1 Decline Predicts Lung Transplant Survival

Prognostic Value of Pre-Diagnostic Lung Function Trajectories

Chronic lung allograft dysfunction remains the primary barrier to long-term survival following lung transplantation, representing a heterogeneous spectrum of immune-mediated graft injury [1, 2, 3]. The condition involves a complex interplay of innate and adaptive immune responses that lead to progressive, often irreversible, tissue remodeling and airway obstruction [4]. While various immunomodulatory strategies such as extracorporeal photopheresis (a procedure where white blood cells are treated with a photosensitizing agent and ultraviolet light to modulate the immune response) and macrolide antibiotics are employed to stabilize graft function, clinical responses remain highly variable among recipients [5, 6]. Current diagnostic criteria focus on a sustained decline in forced expiratory volume in 1 s (the volume of air exhaled during the first second of a forced breath), yet these markers often fail to capture the individual pace of disease progression. Recent data indicate that the rate of forced expiratory volume in 1 s decline among nonsurvivors is significantly higher at -148 milliliters per month compared to -77 milliliters per month in survivors (p = 0.0001) [7]. A new study examines whether the specific trajectory of lung function loss leading up to a formal diagnosis can serve as a reliable predictor of future graft failure and mortality.

Stratifying Risk by Pre-Diagnostic Trajectory

The researchers evaluated a cohort of 293 first lung transplant recipients who were diagnosed with either probable or definite chronic lung allograft dysfunction (a clinical syndrome characterized by a persistent, obstructive decline in lung function) between January 1, 2000, and January 1, 2020. This study population was divided by the specific surgical procedure performed, consisting of 162 bilateral orthotopic lung transplant recipients and 131 single orthotopic lung transplant recipients. By analyzing data over this 20 year period, the study aimed to determine if the physiological behavior of the graft in the months leading up to a formal diagnosis could provide actionable prognostic information for clinicians. This longitudinal approach is particularly relevant because it shifts the focus from a single point in time to the velocity of decline, which may better reflect the underlying intensity of the alloimmune response.

Post-Diagnosis Lung Function and Mortality

The primary focus of the analysis was the trajectory of the forced expiratory volume in 1 s during the three months immediately preceding the onset of chronic lung allograft dysfunction. Based on the slope of this decline, the researchers categorized patients into three distinct groups: slow, intermediate, or rapid progressors. In the cohort of 162 bilateral orthotopic lung transplant recipients, the rate of pre-diagnosis decline served as a clear indicator of subsequent graft performance. The researchers found that intermediate and rapid progressors had significantly lower forced expiratory volume in 1 s at 3 months post-diagnosis when compared with the slow progression group. This physiological deficit persisted as the disease progressed, with intermediate and rapid progressors also demonstrating significantly lower forced expiratory volume in 1 s at 6 months post-diagnosis than their slow-declining counterparts. Similar trends were observed in the forced vital capacity (the total volume of air a patient can exhale after a deep inhalation). Specifically, intermediate and rapid progressors had significantly lower forced vital capacity at 3 months post-diagnosis and continued to show significantly lower forced vital capacity at 6 months post-diagnosis compared with slow progressors.

The predictive value of early lung function trajectories remained evident among the 131 single orthotopic lung transplant recipients, particularly for those with the most aggressive pre-diagnosis declines. In this group, rapid progressors had significantly lower forced expiratory volume in 1 s at 3 months post-diagnosis and significantly lower forced expiratory volume in 1 s at 6 months post-diagnosis. The restrictive and obstructive patterns were further reflected in the forced vital capacity measurements, where rapid progressors had significantly lower forced vital capacity at 3 months post-diagnosis as well as significantly lower forced vital capacity at 6 months post-diagnosis. These findings suggest that the velocity of lung function loss in the three months prior to a formal diagnosis is a critical determinant of the post-diagnosis clinical course regardless of the transplant type. Beyond functional measurements, the study established a direct link between pre-diagnosis trajectories and survival outcomes, finding that mortality was increased in intermediate and rapid progressors compared with slow progressors.

Predictive Modeling for Clinical Intervention

To refine the prognostic utility of these findings, the researchers employed an adjusted Cox proportional hazards regression model (a statistical method used to determine the risk of an event occurring over time while accounting for multiple variables simultaneously). In this analysis of the entire cohort, rapid pre-diagnosis progression was associated with an increased hazard of chronic lung allograft dysfunction progression. The model also identified that a higher chronic lung allograft dysfunction stage at the time of diagnosis was associated with an increased hazard of progression. These findings indicate that both the velocity of initial lung function loss and the severity of the disease at presentation are independent and significant predictors of future graft deterioration.

The clinical implications of these data are centered on the ability to risk-stratify patients at the earliest possible point of intervention. The study demonstrates that rates of forced expiratory volume in 1 s decline in the 3 months before onset predict progression and mortality after onset in both bilateral and single transplant recipients. For the practicing clinician, this 3 month trajectory serves as a critical physiological marker that can distinguish between patients likely to remain stable and those requiring more aggressive management or early referral for re-transplantation evaluation. Furthermore, the authors suggest that the ability to predict the clinical course at the time of diagnosis could help enrich future interventional trials by ensuring that high-risk cohorts are accurately identified and enrolled, potentially allowing for more targeted testing of potent immunosuppressive agents in those with the most aggressive disease phenotypes.

References

1. Fisher AJ, White M, Goudie N, et al. Extracorporeal photopheresis (ECP) in the treatment of chronic lung allograft dysfunction (CLAD): a prospective, multicentre, open-label, randomised controlled trial studying the addition of ECP to standard care in the treatment of bilateral lung transplant patients with CLAD (E-CLAD UK).. BMJ open respiratory research. 2024. doi:10.1136/bmjresp-2023-001995

2. Meyer KC, Raghu G, Verleden GM, et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. European Respiratory Journal. 2014. doi:10.1183/09031936.00107514

3. Royer P, Olivera-Botello G, Koutsokera A, et al. Chronic Lung Allograft Dysfunction: A Systematic Review of Mechanisms.. Transplantation. 2016. doi:10.1097/TP.0000000000001215

4. Bos S, Filby AJ, Vos R, Fisher AJ. Effector immune cells in chronic lung allograft dysfunction: A systematic review.. Immunology. 2022. doi:10.1111/imm.13458

5. Huang H, Kato T, Imamura Y, et al. Prophylactic azithromycin for chronic lung allograft dysfunction following lung transplantation: a systematic review and meta-analysis.. Journal of thoracic disease. 2025. doi:10.21037/jtd-2025-365

6. Benden C, Haughton M, Leonard S, Huber LC. Therapy options for chronic lung allograft dysfunction-bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: A systematic review.. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2017. doi:10.1016/j.healun.2017.05.030

7. Byers DE, Hachem R, Hage C, et al. Identification of Surrogate Outcome Biomarkers in Lung Allograft Recipients With Bronchiolitis Obliterans: Implications for Randomized Controlled Trials. Transplantation Direct. 2025. doi:10.1097/TXD.0000000000001857